PMID- 28083151
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2090-6641 (Print)
IS  - 2090-665X (Electronic)
IS  - 2090-665X (Linking)
VI  - 2016
DP  - 2016
TI  - Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen 
      Followed by Thalidomide-Based Regimen in a Saudi Male.
PG  - 7485695
LID - 10.1155/2016/7485695 [doi]
LID - 7485695
AB  - Light chain deposition disease (LCDD) is a rare illness with, as yet, no clear 
      evidence-based guidelines for its treatment. To the best of our knowledge, LCDD 
      has not been previously reported from Saudi Arabia. We present in this report, a 
      38-year-old Saudi male who presented with clinical features suggestive of 
      hypertensive nephropathy but kidney biopsy later revealed the diagnosis of LCDD. 
      His serum creatinine at presentation was 297 mumol/L which came down to 194 mumol/L 
      on treatment with Bortezomib, Cyclophosphamide and Dexamethasone. His 24-hour 
      protein excretion at presentation was 6 g/L which also came down to less than 
      1 g/day. He was later placed on Cyclophosphamide, Thalidomide, and Dexamethasone 
      regimen because of persistent high titres of serum free light chains. He went 
      into remission with undetectable serum free light chains and remained so for 
      three years at the time of writing this report. We conclude that LCDD, though 
      rare, does occur in Saudi population. The treatment of LCDD is challenging but 
      the use of Bortezomib, a proteosome inhibitor, is promising. However, suboptimal 
      response may require further treatment with other therapeutic options such as 
      chemotherapy with alkylating agents or high-dose Melphalan with autologous stem 
      cell transplant.
FAU - Adamu, Bappa
AU  - Adamu B
AUID- ORCID: 0000-0002-6935-3715
AD  - College of Medicine, University of Bisha, Bisha, Saudi Arabia.
FAU - Al-Ghamdi, Mushabab
AU  - Al-Ghamdi M
AD  - College of Medicine, University of Bisha, Bisha, Saudi Arabia.
FAU - Ahmad, Mustafa
AU  - Ahmad M
AD  - Department of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia.
FAU - Alsaad, Khaled O
AU  - Alsaad KO
AUID- ORCID: 0000-0003-3389-9035
AD  - Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, 
      Riyadh, Saudi Arabia.
LA  - eng
PT  - Case Reports
DEP - 20161219
PL  - United States
TA  - Case Rep Nephrol
JT  - Case reports in nephrology
JID - 101598418
PMC - PMC5204089
COIS- None of the authors have any conflict of interests to declare.
EDAT- 2017/01/14 06:00
MHDA- 2017/01/14 06:01
PMCR- 2016/12/19
CRDT- 2017/01/14 06:00
PHST- 2016/10/07 00:00 [received]
PHST- 2016/11/24 00:00 [accepted]
PHST- 2017/01/14 06:00 [entrez]
PHST- 2017/01/14 06:00 [pubmed]
PHST- 2017/01/14 06:01 [medline]
PHST- 2016/12/19 00:00 [pmc-release]
AID - 10.1155/2016/7485695 [doi]
PST - ppublish
SO  - Case Rep Nephrol. 2016;2016:7485695. doi: 10.1155/2016/7485695. Epub 2016 Dec 19.